CDH9 Antibody

What is CDH9 and what are its structural characteristics?

Cadherin-9 (CDH9) is a single-transmembrane protein belonging to the type 2 Cadherin family. The human CDH9 protein contains specific domains including the extracellular region spanning from Gly54 to Ala615 (Accession # Q9ULB4) . CDH9 shares structural similarities with other cadherins, such as CDH6, which consists of 790 amino acids . These cadherins function primarily as cell adhesion molecules that mediate calcium-dependent cell-cell interactions in tissues.

The protein's extracellular domain contains the epitopes most commonly targeted by research antibodies. For example, some polyclonal antibodies specifically target the Pro222 region of the human CDH9 protein , while monoclonal antibodies may target different epitope regions depending on the specific clone.

In which tissues is CDH9 expression detected?

CDH9 expression has been documented in several human tissues, with notable expression in the lung. Immunohistochemical studies using anti-human CDH9 monoclonal antibodies have demonstrated specific staining localized to the cell surface in human lung tissue samples . Unlike some other cadherins that show broad expression patterns, CDH9 exhibits a more restricted tissue distribution.

It's important to note the distinction between CDH9 and other cadherin family members such as CDH6, which is expressed in several cancer types including serous-type ovarian cancer and renal cell carcinoma . When studying cadherin expression patterns, researchers should be careful to use antibodies with validated specificity to avoid cross-reactivity with other cadherin family members.

What are the primary applications for CDH9 antibodies in research?

CDH9 antibodies have several validated research applications:

For immunohistochemical applications, CDH9 has been successfully detected in immersion-fixed paraffin-embedded sections using monoclonal antibodies at concentrations of approximately 5 μg/ml with incubation periods of 1 hour at room temperature .

How should epitope retrieval be optimized for CDH9 detection in FFPE tissues?

Effective epitope retrieval is crucial for successful CDH9 detection in formalin-fixed paraffin-embedded (FFPE) tissues. The optimal protocol based on published data includes:

• Heat-induced epitope retrieval using basic pH antigen retrieval reagents (e.g., VisUCyte Antigen Retrieval Reagent-Basic)

• Complete epitope retrieval before primary antibody incubation

• Optimization of retrieval time and temperature based on tissue type and fixation duration

It's worth noting that inadequate epitope retrieval is one of the most common causes of false-negative results in CDH9 immunohistochemistry. The cross-linking effect of formalin fixation can mask the CDH9 epitope, particularly in the extracellular domain regions (Gly54-Ala615), requiring efficient retrieval methods .

When troubleshooting weak or absent staining, consider extending the epitope retrieval time or testing alternative pH conditions while maintaining appropriate positive and negative controls to validate any protocol modifications.

What controls should be implemented when validating a new CDH9 antibody?

Comprehensive validation of a new CDH9 antibody requires multiple control strategies:

• Positive tissue controls: Human lung tissue sections have been validated as appropriate positive controls for CDH9 antibodies, demonstrating specific cell surface staining patterns

• Negative controls: Include:

  • Primary antibody omission

  • Isotype-matched irrelevant antibody controls

  • Tissues known to be negative for CDH9 expression

• Specificity controls:

  • Peptide competition assays using the immunizing peptide

  • Comparison with alternative antibody clones targeting different CDH9 epitopes

  • Western blot analysis to confirm correct molecular weight detection

• Cross-reactivity assessment:

  • Testing on tissues expressing other cadherin family members to ensure specificity

  • Particular attention to distinguish between CDH9 and closely related cadherins like CDH6

Implementing these controls systematically ensures that experimental results accurately reflect CDH9 expression rather than artifacts or cross-reactivity issues.

What are the optimal antibody dilutions and incubation conditions for CDH9 detection?

While optimal antibody dilutions should be determined empirically for each specific application and antibody preparation, published research provides useful starting parameters:

For immunohistochemistry applications, monoclonal anti-human CDH9 antibodies have shown effective results at concentrations of approximately 5 μg/ml with incubation times of 1 hour at room temperature . When using polymer-based detection systems such as Anti-Mouse IgG VisUCyte HRP Polymer Antibody, this concentration range provides a good signal-to-noise ratio.

A systematic titration approach is recommended:

• Begin with the manufacturer's recommended concentration range

• Perform a dilution series (e.g., 2.5, 5, and 10 μg/ml)

• Assess both signal intensity and background levels

• Select the dilution providing optimal specific staining with minimal background

Incubation conditions may be modified based on antibody affinity and tissue characteristics. For low-abundance targets, extended incubation times (overnight at 4°C) may enhance sensitivity while maintaining specificity.

What statistical approaches are most appropriate for analyzing CDH9 antibody data?

The analysis of CDH9 antibody data requires careful statistical consideration, particularly when quantifying expression levels or determining positive versus negative staining thresholds:

When analyzing CDH9 expression data:

• For continuous measurement data (e.g., ELISA or quantitative IHC):

  • Consider whether the distribution is skewed (often negatively skewed in seropositive populations)

  • Apply appropriate transformations (often log10) to normalize the data

  • Use mixture models to distinguish positive from negative populations

• For categorical scoring (e.g., positive/negative or intensity scales):

  • Establish clear scoring criteria based on staining intensity and distribution

  • Employ multiple independent scorers to ensure reproducibility

  • Calculate inter-observer agreement using kappa statistics

The choice of statistical model can significantly impact data interpretation. For instance, using Skew-Normal distributions might be more appropriate than standard Normal distributions when there is evidence of asymmetry in CDH9 expression data .

How can contradictory CDH9 expression results between different techniques be reconciled?

Contradictory results between different detection methods (e.g., IHC vs. Western blot) are a common challenge in CDH9 research. A systematic approach to reconciling these differences includes:

• Epitope accessibility assessment:

  • Different techniques expose different epitopes

  • IHC may detect native conformation epitopes that are lost in denatured Western blot samples

  • Polyclonal antibodies targeting multiple epitopes (e.g., Pro222 region) may perform differently across techniques compared to monoclonal antibodies

• Reagent validation:

  • Confirm antibody specificity in each application separately

  • Use multiple antibodies targeting different CDH9 epitopes

  • Implement proper positive and negative controls for each technique

• Complementary methods approach:

  • Employ orthogonal techniques (e.g., mRNA analysis via RT-PCR)

  • Use genetic approaches (siRNA knockdown) to validate antibody specificity

  • Consider functional assays that detect CDH9-dependent cellular behaviors

• Technical considerations:

  • Ensure optimal sample preparation for each technique (fixation for IHC, lysis conditions for Western blot)

  • Optimize detection systems for each method independently

  • Account for differences in sensitivity thresholds between methods

When reconciling contradictory results, researchers should remember that different techniques may detect different aspects of CDH9 biology (e.g., total protein vs. cell surface expression), and these differences may reflect true biological phenomena rather than technical artifacts.

What are the most reliable cutoff determination methods for CDH9 positivity?

Establishing reliable cutoffs for CDH9 positivity is crucial for accurate data interpretation. Several approaches can be employed:

• Statistical mixture modeling:

  • Finite mixture models using Skew-Normal or Skew-t distributions can help identify natural cutpoints in the data

  • These models account for the asymmetry often observed in antibody data distributions

  • BIC (Bayesian Information Criterion) can be used to select the optimal number of components in the mixture model

• Control-based thresholds:

  • Utilize known positive and negative controls to establish threshold values

  • For immunohistochemistry, compare staining intensity to internal positive controls

  • Account for tissue-specific background staining levels

• ROC curve analysis:

  • When correlating with a gold standard or clinical outcome

  • Select cutoff values that maximize both sensitivity and specificity

  • Report area under the curve (AUC) values to indicate discriminatory power

It's important to note that cutoff values may vary between different antibody clones, detection systems, and laboratory protocols. For instance, when using antibody concentration as a measure (U/ml), manufacturers may recommend specific cutoff values (e.g., ≤8 U/ml for seronegative or ≥12 U/ml for seropositive) , but these should be validated in each laboratory's specific conditions.

How can CDH9 antibodies be utilized in multiplexed detection systems?

Multiplexed detection involving CDH9 requires careful consideration of antibody compatibility and detection systems:

• Antibody selection criteria:

  • Choose primary antibodies from different host species to avoid cross-reactivity

  • Select CDH9 antibodies with validated specificity to prevent cross-reaction with other cadherin family members

  • Consider the subcellular localization pattern (cell surface for CDH9) when designing multiplexed panels

• Sequential multiplex protocols:

  • For brightfield IHC multiplex, consider sequential chromogenic detection with different substrates

  • For fluorescent multiplex, use directly conjugated antibodies or different secondary detection systems

  • Include appropriate controls for each marker in the multiplex panel

• Signal separation strategies:

  • Use spectral unmixing for fluorescent multiplex applications

  • Employ serial section analysis for challenging combinations

  • Consider tyramide signal amplification for low-abundance targets

• Validation requirements:

  • Compare multiplex results with single-marker controls

  • Confirm expected co-localization or mutual exclusivity patterns

  • Verify that sensitivity is not compromised in the multiplex format

When designing multiplexed panels including CDH9, researchers should consider the biological context and select complementary markers that address the specific research question, such as epithelial markers, other cell adhesion molecules, or cancer-specific markers when studying pathological samples.

What are the considerations for using CDH9 antibodies in studying protein-protein interactions?

Investigating CDH9 interactions with other proteins requires specialized approaches:

• Co-immunoprecipitation (Co-IP) considerations:

  • Select CDH9 antibodies that don't interfere with potential interaction domains

  • Consider antibodies targeting different epitopes (e.g., Pro222 region) to avoid disrupting specific interactions

  • Use mild lysis conditions to preserve native protein complexes

  • Include appropriate negative controls (isotype-matched irrelevant antibodies)

• Proximity ligation assay (PLA) approach:

  • Combine CDH9 antibodies with antibodies against suspected interaction partners

  • Ensure antibodies are from different host species or use directly conjugated primary antibodies

  • Optimize fixation and permeabilization to maintain both antigenicity and protein localization

• Functional validation strategies:

  • Complement antibody-based detection with genetic approaches

  • Correlate detected interactions with functional outcomes

  • Validate interactions using multiple, orthogonal techniques

• Technical limitations awareness:

  • Consider that antibodies may stabilize or disrupt specific interactions

  • Be aware that fixation can create artificial cross-linking between proteins

  • Account for the potential loss of transient or weak interactions during processing

When studying CDH9 interactions, researchers should consider its known role as a cell adhesion molecule and focus on potential interactions with cytoskeletal components, signaling molecules, and other membrane proteins that might participate in cell-cell adhesion complexes.